secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001193125-22-177774
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Atea Pharmaceuticals stockholders elect three Class II directors, approve 'one year' say-on-pay frequency
--------------------------------------------------------------------------------

- Elected Bruno Lucidi, Polly A. Murphy, and Bruce Polsky as Class II directors (over 55.7M votes each, no broker non-votes included).
- Advisory vote on executive compensation frequency: ONE year approved with 59,857,505 votes for (99.4% of votes cast).
- Ratification of KPMG LLP as independent auditor for 2022 passed with 71,630,493 votes for, 281,592 against, 35,490 abstain.
- Approximately 86.41% of outstanding shares were represented at the meeting (71,947,575 shares of common stock).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522177774/0001193125-22-177774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312522177774/d916865d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-177774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer